




**This is a joint industry presentation on behalf
of the trade associations shown**



Brexit: Putting patients first #Brexit4patients

Industry priority to ensure outcome of Brexit negotiations **maintains supply of medicines and medical technologies to patients across Europe and maximises public health across Europe.**

Brexit has potential to impact on patients in the UK and the EU.



How does Brexit impact the supply of medicines & medical technologies?

Manufacturing and supply

Quality testing

QP release

GxP inspections

OMCL

Regulatory

MHRA no longer part of EMA

Licence transfer

Change of rapporteurships for centralised procedure and of RMS for DCP

Changes on package leaflet & artwork

CE label

Trade and tax

New border arrangements may result in tariffs and border delays.

So far there is no clarity – IT systems, customs brokers, infrastructure, custom officials?

People

EU nationals will no longer have the automatic right to work in the UK and vice versa.

What does it mean for our employees and our programmes

R&D

UK life science basis

H2020/IMI

Horizon Europe

Prioritise public health & supply of medicines & medical technologies in the negotiations

Short term solutions:

- An MRA on quality testing, GxP testing, CE marked medical technologies
- Clarity on borders, including IT systems to be used
- Governments/EC to make sure preparedness plans are in place
- Horizon Europe allowing for UK participation

Medium/long term solutions:

- A relationship that allows to cooperate where it makes sense
- A way for MHRA to plug into EMA & Eudamed workings
- Quick border procedures with no custom duties for medicines and healthcare products
- Immigration systems that allow the best talent to work together